News Focus
News Focus
Followers 7
Posts 388
Boards Moderated 0
Alias Born 07/18/2016

Re: None

Wednesday, 06/30/2021 3:04:15 PM

Wednesday, June 30, 2021 3:04:15 PM

Post# of 517424
Has this been posted yet?

From the European Patent Office: ANAVEX2-73 FOR THE TREATMENT OF GENETIC NEURODEVELOPMENTAL DISORDERS:

The first group, known as the Aneuploidy group, comprises disorders caused by an abnormal number of chromosomes. The primary example in this group is Down’s syndrome.



The second group consists of disorders chromosomal micro-deletions, such as the deletion of a chromosomal region. Examples in this group are William’s Beuren syndrome, Prader-Willi syndrome, Angelman syndrome, Smith-Magenis syndrome, and velo-cardio-facial syndrome.



The third group consists of disorders having a single gene defect. Examples in this group are ATR-X syndrome, Barth syndrome, Fragile X- syndrome, ICF syndrome, Neurofibromatosis, Rett syndrome, and Smith-Lemli-Opitz syndrome.



The last group is believed to be caused by a combination of genetic, environmental, and epigenetic factors. Examples in this group are addictive disorders, ADHD, anxiety disorders, Asperger’s syndrome, autistic disorders, depression, dyslexia, eating disorders, epilepsy, infantile spasms, fetal alcohol syndrome, hydrocephalus, manic depressive illness, mental retardation, schizophrenia, spina bifida, and Tourette’s syndrome.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News